An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
NCT ID: NCT06129812
Last Updated: 2023-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1132 participants
OBSERVATIONAL
2007-01-31
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.
NCT04835064
Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade
NCT06630481
Prospective Cohort Study of Pancreatic Cancer Patients Treated With Proton Beam Therapy
NCT04466189
Clinical Outcomes of Surgery After Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
NCT05888129
Intraoperative Radiation Therapy for Resectable Pancreatic Cancer
NCT05181488
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
resectable PDAC with no contact to major vessels (R-no contact)
Neoadjuvant treatment
Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.
resectable PDAC with contact PV/SMV of ≤180° (R-contact)
Neoadjuvant treatment
Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.
borderline resectable PDAC with PV/SMV contact >180° and without arterial involvement (BR-V)
Neoadjuvant treatment
Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neoadjuvant treatment
Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between January 2007 and June 2021 at Seoul National University Hospital
Exclusion Criteria
* Patients who received chemotherapy as initial treatment and did not undergo surgery
* Incomplete follow-up data for analysis
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NAT in resectable PDAC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.